Chimeric Antigen Receptor System for Signalling

ChangeBridge: Patent Apps - Peptides (C07K)

Published March 26th, 2026

Detected March 26th, 2026

Summary

The USPTO has published a new patent application, US20260085106A1, detailing a chimeric antigen receptor (CAR) system. This system is designed to control signalling based on the presence or absence of a specific agent, potentially impacting the development of targeted therapies.

View original document View source feed page

What changed

This document is a published patent application (US20260085106A1) from the USPTO concerning a novel chimeric antigen receptor (CAR) system. The system features a receptor component and a signalling component that heterodimerize in the absence of a specific agent, enabling antigen binding to trigger signalling. In the presence of the agent, heterodimerization is disrupted, preventing signalling. This mechanism allows for controlled activation of CARs.

While this is a patent application and not a regulation, it signals innovation in the field of targeted therapies, particularly for drug manufacturers and medical device makers. Compliance officers in these sectors should be aware of emerging technologies that may lead to future regulatory considerations or intellectual property landscapes. No immediate compliance actions are required, but monitoring patent filings in this area can provide insights into future therapeutic developments.

Source document (simplified)

← USPTO Patent Applications

Signalling System

Application US20260085106A1 Kind: A1 Mar 26, 2026

Inventors

Martin Pulé, Shaun Cordoba, Simon Thomas, Shimobi Onuoha, Maria Stavrou

Abstract

The present invention provides a chimeric antigen receptor (CAR) system comprising; (i) a receptor component comprising a antigen binding domain and a first binding domain; and (ii) a signalling component comprising a signalling domain and a second binding domain which binds the single domain binder of the first binding domain of the receptor component wherein either the first or second binding domains comprise a single domain binder, and wherein, binding of the first and second binding domains is disrupted by the presence of an agent, such that in the absence of the agent, the receptor component and the signalling component heterodimerize and binding of the antigen binding domain to antigen results in signalling through the signalling domain; whereas in the presence of the agent, the receptor component and the signalling component do not heterodimerize and binding of the antigen binding domain to antigen does not result in signalling through the signalling domain.